ArticleGynecologic oncology reports2026

Real World Outcomes of Pembrolizumab and Reduced-Dose Lenvatinib in Recurrent Endometrial Cancer by Platinum and p53 Status.

Alexa Dzienny et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.